
Raymon H Grogan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10777537/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery, 2013, 154, 1436-1447.	1.9	239
2	The Clinical and Economic Burden of a Sustained Increase in Thyroid Cancer Incidence. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1252-1259.	2.5	191
3	Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma. Thyroid, 2016, 26, 807-815.	4.5	149
4	Quality of Life in Thyroid Cancer is Similar to That of Other Cancers with Worse Survival. World Journal of Surgery, 2016, 40, 551-561.	1.6	142
5	Risk Factors for Decreased Quality of Life in Thyroid Cancer Survivors: Initial Findings from the North American Thyroid Cancer Survivorship Study. Thyroid, 2015, 25, 1313-1321.	4.5	118
6	Follicular Thyroid Cancer Incidence Patterns in the United States, 1980–2009. Thyroid, 2013, 23, 1015-1021.	4.5	107
7	The Breast–Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 231-238.	2.5	103
8	Thyroid Nodule Size at Ultrasound as a Predictor of Malignancy and Final Pathologic Size. Thyroid, 2017, 27, 641-650.	4.5	85
9	The Acceleration in Papillary Thyroid Cancer Incidence Rates is Similar Among Racial and Ethnic Groups in the United States. Annals of Surgical Oncology, 2013, 20, 2746-2753.	1.5	82
10	An update in international trends in incidence rates of thyroid cancer, 1973–2007. Cancer Causes and Control, 2018, 29, 465-473.	1.8	70
11	Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism. JAMA Surgery, 2019, 154, e185842.	4.3	68
12	Follicular Thyroid Carcinoma: How Have Histologic Diagnoses Changed in the Last Half-Century and What Are the Prognostic Implications?. Thyroid, 2015, 25, 1209-1216.	4.5	64
13	Changing Paradigms in the Treatment of Malignant Pheochromocytoma. Cancer Control, 2011, 18, 104-112.	1.8	55
14	Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery, 2019, 165, 221-227.	1.9	52
15	Sociodemographic Disparities in Differentiated Thyroid Cancer Survival Among Adolescents and Young Adults in California. Thyroid, 2015, 25, 635-648.	4.5	51
16	The Evolution of Biomarkers in Thyroid Cancer—From Mass Screening to a Personalized Biosignature. Cancers, 2010, 2, 885-912.	3.7	49
17	Incidence, Risk Factors, and Clinical Outcomes of Incidental Parathyroidectomy During Thyroid Surgery. Annals of Surgical Oncology, 2016, 23, 4310-4315.	1.5	49
18	Benign and Malignant Thyroid Incidentalomas Are Rare in Routine Clinical Practice: A Review of 97,908 Imaging Studies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1327-1331.	2.5	42

RAYMON H GROGAN

#	Article	IF	CITATIONS
19	Primary Hyperparathyroidism Patients with Positive Preoperative Sestamibi Scan and Negative Ultrasound Are More Likely to Have Posteriorly Located Upper Gland Adenomas (PLUGs). Annals of Surgical Oncology, 2011, 18, 1717-1722.	1.5	40
20	Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocrine-Related Cancer, 2016, 23, 171-179.	3.1	39
21	Patient Eligibility for Transoral Endocrine Surgery Procedures in the United States. JAMA Network Open, 2019, 2, e194829.	5.9	39
22	Normohormonal primary hyperparathyroidism is a distinctÂform of primary hyperparathyroidism. Surgery, 2017, 161, 62-69.	1.9	36
23	Hurthle cell carcinoma: An update on survival over the last 35 years. Surgery, 2013, 154, 1263-1271.	1.9	35
24	The Incidence and Survival of Rare Cancers of the Thyroid, Parathyroid, Adrenal, and Pancreas. Annals of Surgical Oncology, 2016, 23, 424-433.	1.5	35
25	Adrenal incidentaloma: Does an adequate workup rule out surprises?. Surgery, 2010, 148, 392-397.	1.9	31
26	Adenoma Localization for Recurrent or Persistent Primary Hyperparathyroidism Using Dynamic Four-Dimensional CT and Venous Sampling. Journal of Vascular and Interventional Radiology, 2015, 26, 79-86.	0.5	31
27	Ultrasonic, bipolar, and integrated energy devices: comparing heat spread in collateral tissues. Journal of Surgical Research, 2017, 207, 249-254.	1.6	31
28	Quality of life in thyroid cancer—assessment of physician perceptions. Journal of Surgical Research, 2018, 226, 94-99.	1.6	30
29	Variation of Thyroidectomy-Specific Outcomes Among Hospitals and Their Association With Risk Adjustment and Hospital Performance. JAMA Surgery, 2018, 153, e174593.	4.3	30
30	Large Cytologically Benign Thyroid Nodules Do Not Have High Rates of Malignancy or False-Negative Rates and Clinical Observation Should be Considered: A Meta-Analysis. Thyroid, 2018, 28, 1595-1608.	4.5	26
31	One-hour PTH after thyroidectomy predicts symptomatic hypocalcemia. Journal of Surgical Research, 2016, 201, 473-479.	1.6	23
32	Robot-Assisted Endocrine Surgery: Indications and Drawbacks. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2019, 29, 129-135.	1.0	23
33	Clinical outcomes after surgery for primary aldosteronism: Evaluation of the PASO-investigators' consensus criteria within a worldwide cohort of patients. Surgery, 2019, 166, 61-68.	1.9	21
34	Localization of Parathyroid Disease in Reoperative Patients with Primary Hyperparathyroidism. International Journal of Endocrinology, 2020, 2020, 1-15.	1.5	21
35	What's in a Name?: Providing Clarity in the Definition of Minimally Invasive Parathyroidectomy. World Journal of Surgery, 2015, 39, 975-980.	1.6	19
36	Epigenetic Alterations and Canonical Pathway Disruption in Papillary Thyroid Cancer: A Genome-wide Methylation Analysis. Annals of Surgical Oncology, 2016, 23, 2302-2309.	1.5	19

RAYMON H GROGAN

#	Article	IF	CITATIONS
37	Failure to Diagnose and Treat Hyperparathyroidism Among Patients with Hypercalcemia: Opportunities for Intervention at the Patient and Physician Level to Increase Surgical Referral. Oncologist, 2019, 24, e828-e834.	3.7	19
38	Preoperative calcitriol reduces postoperative intravenous calcium requirements and length of stay in parathyroidectomy for renal-origin hyperparathyroidism. Surgery, 2019, 165, 151-157.	1.9	16
39	Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1Âcm. Langenbeck's Archives of Surgery, 2016, 401, 365-373.	1.9	15
40	Leontiasis ossea caused by long-standing hyperparathyroidism secondary to chronic renal failure. Surgery, 2014, 156, 1644-1646.	1.9	14
41	Age of diagnosing physician impacts the incidence of thyroid cancer in a population. Cancer Causes and Control, 2014, 25, 1627-1634.	1.8	11
42	A novel, ultrarapid parathyroid hormone assay to distinguish parathyroid from nonparathyroid tissue. Surgery, 2014, 156, 1638-1643.	1.9	11
43	Transoral endocrine surgery: Considerations for adopting a new technique. Journal of Surgical Oncology, 2020, 122, 36-40.	1.7	10
44	Clinical Translation and Evaluation of a Handheld and Biocompatible Mass Spectrometry Probe for Surgical Use. Clinical Chemistry, 2021, 67, 1271-1280.	3.2	10
45	Development of the ThyCAT: A clinically useful computerized adaptive test to assess quality of life in thyroid cancer survivors. Surgery, 2018, 163, 137-142.	1.9	9
46	Interventions to improve thyroid cancer survivors' quality of life. Future Oncology, 2016, 12, 1309-1311.	2.4	8
47	Preferences for thyroidectomy technique: Comparing traditional and transoral approaches. Head and Neck, 2021, 43, 1747-1758.	2.0	8
48	Radiation-Induced Differentiated Thyroid Cancer Is Associated with Improved Overall Survival but Not Thyroid Cancer–Specific Mortality or Disease-Free Survival. Thyroid, 2016, 26, 1053-1060.	4.5	7
49	A novel technique to improve theÂdiagnostic yield of negative sestamibi scans. Surgery, 2014, 156, 584-590.	1.9	5
50	Re: Brito <i>et al.</i> , Overdiagnosis of Thyroid Cancer and Graves' Disease. Thyroid, 2014, 24, 403-404.	4.5	4
51	The Importance of Family History in the Management of Endocrine Disease. Surgical Clinics of North America, 2019, 99, 711-720.	1.5	4
52	What's in a Name? Providing Clarity in the Definition of Minimally Invasive Parathyroidectomy: Reply. World Journal of Surgery, 2015, 39, 2842-2843.	1.6	3
53	Public Perceptions of Transoral Endocrine Surgery and their Influence on Choice of Operative Approach. Journal of Surgical Research, 2021, 267, 56-62.	1.6	3
54	A simplified primary aldosteronism surgical outcome score is a useful prediction model when target organ damage is unknown – Retrospective cohort study. Annals of Medicine and Surgery, 2021, 65, 102333.	1.1	2

RAYMON H GROGAN

#	Article	IF	CITATIONS
55	Thyroid incidentalomas and the overdiagnosis conundrum. International Journal of Endocrine Oncology, 2016, 3, 193-196.	0.4	1
56	Individual patient and population-level eligibility for transoral endocrine surgery. Annals of Thyroid, 0, 5, 10-10.	1.0	1
57	Transoral Endoscopic Thyroidectomy Vestibular Approach Complications and Safety: Reporting Objectives and Future Study Design. , 2020, , 281-292.		1
58	A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands. Head and Neck Pathology, 2018, 12, 286-290.	2.6	0
59	One hundred and one consecutive transoral endoscopic parathyroidectomies via the vestibular approach for PHPTH: a worldwide multi-institutional experience. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 4821-4827.	2.4	0